B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial

Journal of the American College of Cardiology

Volumn 73, Issue 11, 2019, Pages 1264-1272

  Myhre, Peder Langeland ^a,b   Vaduganathan, Muthiah ^a   Claggett, Brian ^a   Packer, Milton ^c   Desai, Akshay S ^a   Rouleau, Jean L ^d   Zile, Michael R ^e   Swedberg, Karl ^f   Lefkowitz, Martin ^g   Shi, Victor ^g   McMurray, John J V ^h   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

biomarker; heart failure; natriuretic peptides; prognostication; risk stratification; treatment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SACUBITRIL-VALSARTAN; TETRAZOLE DERIVATIVE;

ACCURACY; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETER); CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; HEART FAILURE;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIOMARKERS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 85062708969     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.01.018     Document Type: Article

References (24)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
2. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
3. Clerico, A., Fontana, M., Zyw, L., Passino, C., Emdin, M., Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 53 (2007), 813–822.
4. Hammerer-Lercher, A., Collinson, P., van Dieijen-Visser Marja, P., et al. Do laboratories follow heart failure recommendations and guidelines and did we improve? The cardiac marker Guideline Uptake in Europe (CARMAGUE). Clin Chem Lab Med, 2013, 1301.
5. Mcmurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
6. Pankow, K., Schwiebs, A., Becker, M., Siems, W.E., Krause, G., Walther, T., Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol 393 (2009), 496–503.
7. Walther, T., Stepan, H., Pankow, K., Becker, M., Schultheiss, H.P., Siems, W.E., Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol Chem 385 (2004), 179–184.
8. Nougué H., Pezel, T., Picard, F., et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail, 2018 Dec 6 [E-pub ahead of print].
9. Yancy, C.W., Januzzi, J.L. Jr., Allen, L.A., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 71 (2018), 201–230.
10. Lippi, G., Sanchis-Gomar, F., Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?. Int J Cardiol 219 (2016), 111–114.
11. Ibrahim, N.E., Januzzi, J., Monitoring biomarkers in patients receiving neprilysin inhibitors. Curr Emerg Hosp Med Rep 6 (2018), 8–16.
12. Mcmurray, J.J., Packer, M., Desai, A.S., et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15 (2013), 1062–1073.
13. Zile, M.R., Claggett, B.L., Prescott, M.F., et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 68 (2016), 2425–2436.
14. Mair, J., Lindahl, B., Giannitsis, E., et al. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?. Eur Heart J Acute Cardiovasc Care 6 (2017), 321–328.
15. Volpe, M., Rubattu, S., Burnett, J.J., Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 35 (2014), 419–425.
16. Semenov, A.G., Katrukha, A.G., Different susceptibility of B-type natriuretic peptide (BNP) and BNP precursor (probnp) to cleavage by neprilysin: the N-terminal part does matter. Clin Chem 62 (2016), 617–622.
17. Packer, M., Mcmurray, J.J., Desai, A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
18. Myhre, P.L., Vaduganathan, M., Claggett, B.L., et al. Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol 3 (2018), 1000–1005.
19. Velazquez, E.J., Morrow, D.A., Devore, A.D., et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med, 2018 Nov 11 [E-pub ahead of print].
20. Seferian, K.R., Tamm, N.N., Semenov, A.G., et al. Immunodetection of glycosylated NT-probnp circulating in human blood. Clin Chem 54 (2008), 866–873.
21. Mair, J., Clinical significance of pro-B-type natriuretic peptide glycosylation and processing. Clin Chem 55 (2009), 394–397.
22. Luckenbill, K.N., Christenson, R.H., Jaffe, A.S., et al. Cross-reactivity of BNP, NT-probnp, and probnp in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 54 (2008), 619–621.
23. Nowatzke, W.L., Cole, T.G., Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem 49 (2003), 1560–1562.
24. Januzzi, J.L., Butler, J., Fombu, E., et al. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). Am Heart J 199 (2018), 130–136.